An accident which saw a woman trip and fall outside a hospital led to her death, a coroner has found. Lorna Loxton, a former ...

Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...

Dyne Therapeutics, Inc. (NASDAQ:DYN) is among the 14 best booming stocks to buy right now, with returns of over 23% in the ...

Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of ...

Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

An analysis of genetic data from over 900,000 people shows that certain stretches of DNA, made up of short sequences repeated ...

Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 - -- Expects to initiate global Phase 1/2 MAD clinical study ...

Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –-- ...

As of Thursday, January 08, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.03%, which has investors questioning if ...

An analysis of genetic data from over 900,000 people shows that certain stretches of DNA, made up of short sequences repeated ...

An analysis of genetic data from over 900,000 people shows that certain stretches of DNA, made up of short sequences repeated ...